Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Discover OncologyOpen Access

Knowledge-map and bibliometric analysis of scientific research on FDA-approved Chimeric Antigen Receptor T cell products (2015–2024)

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMoutaz W Sweileh

Discussion

Loading...

Member takes

Overview

Analysis reveals significant trends in car-t therapy research in oncology, suggesting evolving priorities in treatment approaches.

Key Points

  • The bibliometric analysis shows a rapid growth in publications on car-t therapy, especially tisa-cel and axi-cel.
  • From 2015 to 2024, 1163 documents were published, with an average annual growth rate of 63.4% and a high citation impact.
  • Institutional collaboration is evident, with the University of Texas MD Anderson Cancer Center leading in car-t research output.
  • Emerging themes in research indicate a shift from cd19-targeted therapies to bcma-focused car-t strategies.

Cite This Study

Moutaz W Sweileh (2025) studied this question.

synapsesocial.com/papers/68c1abf154b1d3bfb60e3f16https://doi.org/10.1007/s12672-025-03360-y
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global research trends in CAR-T cell therapy for solid tumors: A comprehensive visualization and bibliometric study (2012–2023)2024 · 21 citations
  2. 2Software survey: VOSviewer, a computer program for bibliometric mapping2009 · 21,330 citations
  3. 3Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma2021 · 1,610 citations
  4. 4Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma2023 · 16 citations
  5. 5CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges2022 · 396 citations